Implementation of National Pediatric Guidelines to Prevent Chemotherapy Induced Nausea and Vomiting in Children with Cancer by Sandheinrich, Taryn
University of Missouri, St. Louis
IRL @ UMSL
Dissertations UMSL Graduate Works
7-11-2018
Implementation of National Pediatric Guidelines to
Prevent Chemotherapy Induced Nausea and
Vomiting in Children with Cancer
Taryn Sandheinrich
tgfqn5@mail.umsl.edu
Follow this and additional works at: https://irl.umsl.edu/dissertation
Part of the Medicine and Health Sciences Commons
This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has been accepted for inclusion in
Dissertations by an authorized administrator of IRL @ UMSL. For more information, please contact marvinh@umsl.edu.
Recommended Citation
Sandheinrich, Taryn, "Implementation of National Pediatric Guidelines to Prevent Chemotherapy Induced Nausea and Vomiting in
Children with Cancer" (2018). Dissertations. 774.
https://irl.umsl.edu/dissertation/774
  
 
Implementation of National Pediatric Guidelines to Prevent Chemotherapy Induced Nausea 
and Vomiting in Children with Cancer 
 
 
 
Taryn Sandheinrich 
M.S.N., Masters of Science in Nursing, University of Missouri-St. Louis, 2014 
B.S.N., Bachelors of Science in Nursing, St. Louis University, 2011 
 
 
A Dissertation Submitted to The Graduate School at the University of Missouri-St. Louis 
in partial fulfillment of the requirements for the degree 
Doctorate of Nursing in Practice 
 
 
August 
2018 
 
 
 
 
Advisory Committee 
 
Susan Dean-Baar, PhD, RN, CENP, FAAN. 
Chairperson 
 
Lisa Merritt, DNP, APRN, CPNP-PC/AC, PMHS. 
 
Deborah Robinson, DNP, MSNR, APRN, PPCNP-BC, CPHON 
 
 
1 
Implementation of National Pediatric Guidelines 
 
 
Abstract 
Purpose: The purpose of this study was to assess the use of supplemental, as needed 
(prn) pharmacologic interventions for uncontrolled acute chemotherapy induced nausea 
and vomiting (CINV) in children with cancer after implementation of new pediatric 
CINV prophylaxis guidelines. Description of Project: A retrospective chart review was 
completed on forty-three children admitted to the hospital for chemotherapy during a 3 
month period in 2017 to document the use of medications given for acute breakthrough 
CINV.   The pre-implementation group received anti-emetics based on the institutional 
standard of care. A second retrospective chart review was completed on thirty-three 
children admitted to the hospital for chemotherapy during a 3 month period in 2018 to 
evaluate use of medications for acute breakthrough CINV. The post-implementation 
group received anti-emetics based on the new published pediatric guidelines. Patient 
characteristics, treatment information, and provider compliance with guidelines were 
collected. Results/Conclusions: Implementation of the guideline by the institution was 
successful with 91% of patients in the post-intervention group receiving the new anti-
emetic regimen to prevent nausea and vomiting.  The mean anti-emetic dose in all 
patients for breakthrough CINV pre-implementation was 4.837±10.4857. Post-
implementation, the mean anti-emetic dose for all patients was 3.394±6.432. This was not 
statistically significant (p =0.462). For patients under 12, the mean anti-emetic dose pre-
implementation was 5.8±12.5333 and post-implementation was 3.882±8.1. This was also 
not statistically significant (p =0.55).   Data collected from this project did demonstrate a 
decrease in the number of breakthrough anti-emetics used in children under 12 years of 
age likely related to the addition of the drug aprepitant.   Although clinical guidelines 
provide excellence guidance to clinicians, they must always be evaluated for risk versus 
benefit; adapted to individual patient circumstances as appropriate; and used within the 
context of expert clinician judgement.  
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Introduction 
Childhood cancer is the second leading cause of death in children 5-14 (Ward, 
DeSantis, Robbins, Kohler, & Jemal,2014). In the United states 1 in 285 children under 
the age of 20 are diagnosed with cancer each year (Ward et al., 2014). Chemotherapy 
induced nausea and vomiting (CINV) is a common side effect that can cause significant 
physical and emotional distress.  Chemotherapy induced nausea and vomiting can be 
divided into different categories. Acute nausea and vomiting includes all episodes each 
day the chemotherapy is administered, and for 24 hours after the last dose. Delayed 
nausea and vomiting starts 24 hours after the last dose and can last up to one week.   
Anticipatory nausea and vomiting occurs prior to chemotherapy administration. It can be 
triggered by smells, tastes, and anxiety (Jordan, Kasper, & Schmoll, 2005).There are 
many risk factors that are associated with a higher incidence of CINV. These include but 
are not limited to female gender, younger age, and previous exposure to highly 
emetogenic agents (Haiderali, Menditto, Good, Teitelbaum, &Wegner, 2011).  
Chemotherapy agents classified as highly emetogenic have a greater than 90% 
frequency of emesis in the absence of prophylaxis (Dupuis et al. 2013).  The majority of 
patients at some time point in their cancer treatment protocol will receive chemotherapy 
classified as highly emetogenic.  Uncontrolled nausea or vomiting from chemotherapy 
causes not only a burden on the patient, it can also impact the overall quality of care 
provided. Some of the direct costs that are associated with managing nausea or vomiting 
symptoms include: additional anti-emetic medications; unplanned doctor visits; 
unexpected hospitalizations, and visits to the emergency room.  Indirect costs of CINV 
include loss of work productivity, and missed work for patient and/or caregiver 
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(Haiderali et al., 2011). In a study by Haiderali et al. (2011), it was estimated that the 
combined indirect and direct cost of CINV per patient per round of chemotherapy was on 
average $778.53 per patient. This number only accounts for the cycle of chemotherapy. 
The standard of care for children with Ewing’s sarcoma is 12 cycles of highly emetogenic 
chemotherapy. That would mean an increased cost of around $9342.36 per patient with 
this diagnosis each year.  
 CINV is one of the most feared side effects prior to chemotherapy treatment, and 
unfortunately it is relatively common.  Anti-emetic medications to control the unwanted 
effects of chemotherapy are available, but they are not always administered according to 
international guidelines. Insufficient administration of anti-emetics can lead to 
suboptimal management of side effects resulting in a significant impact on quality of life 
(QoL) (Lorusso et al., 2016) Many studies have shown that CINV negatively affects QoL 
in patients receiving treatment for malignancy. In a study by Ballatori et al. (2007), more 
than 90% of the patients at 7 different Italian centers with acute and delayed onset CINV 
reported impact on daily life on the Functional Living Index-Emesis (FLIE) 
questionnaire. The FLIE questionnaire is the only validated nausea and vomiting specific 
patient reported outcome tool. 
 Until recently, there had been no pediatric published guidelines for management 
and prophylaxis of CINV. In 2013, The Pediatric Oncology Group of Ontario (POGO) 
published evidence based guidelines for management of CINV in pediatric cancer 
patients. In 2016, the Children’s Oncology Group (COG) the national pediatric clinical 
trial organization supported by the National Cancer Institute (NCI) adopted these 
evidence based guidelines for CINV management. These guidelines have since been 
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amended in 2017. One of the biggest changes in the 2017 guidelines was the use of the 
drug aprepitant for children greater than 6 months of age.  These changes were based on 
recommendations of Patel et al., (2017). Aprepitant is an anti-emetic medication designed 
to treat delayed vomiting, however the original FDA approval for this medication was in 
the adult population and in adolescents greater than 12 years. These evidence based 
guidelines give health care providers an approach to help reduce the incidence of both 
acute and delayed nausea and vomiting caused by chemotherapy in the pediatric 
population (Dupuis et al., 2013).  
Purpose 
          The purpose of this project was to evaluate if there was a decrease in the use of 
supplemental pharmacologic intervention to treat breakthrough acute CINV after 
implementation of new adapted St. Louis Children’s Hospital (SLCH) guidelines based 
on a published evidenced-based national guideline.  The guideline was expected to have 
the most impact on children less than 12 years of age, thus this group was analyzed 
separately. The second purpose was to assess provider compliance with the new 
guideline.  The scope of this project includes only those patients who received highly 
emetic chemotherapy; and the data collection occurred only during the acute phase of 
CINV including all days the patient actually received chemotherapy.   
          The standard definition in the literature for optimal control of acute CINV is stated 
as: no vomiting, no retching, no nausea, and no use of anti-emetic agents other than those 
given for CINV prevention. This level of control is to be achieved on each day of 
chemotherapy administration. For this project, each time a patient received an anti-emetic 
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in a 24 hour period, was considered a failure of the regimen at that point in time. Each 
dose of breakthrough anti-emetics was counted for each day of chemotherapy for all 
patients in the sample.   
Setting 
 This project was completed at a large urban academic pediatric hospital.  The 
hospital has a nationally recognized pediatric oncology program and is an active member 
of the COG. The hospital had developed an institutional standard of care for prophylaxis 
of both acute and delayed vomiting caused by chemotherapy including a defined 
breakthrough regimen.  This institutional standard was based on the adult American 
Society of Clinical Oncology (ASCO) guideline (Basch et al., 2011) and the published 
literature regarding symptom management of pediatric patients receiving chemotherapy.   
The institutional standard was implemented with a general pre-built anti-emetic order set 
with clinical guidance, but it was ultimately left up to the providers to prescribe as they 
desired for their patient’s individual needs and preferences.  
Anti-Emetic Medications 
            There are 3 major categories of anti-emetic agents that will be discussed in this 
project.  5- HT3 receptor antagonists such as ondansetron are the mainstay of treatment 
for acute CINV. Corticosteroids such as dexamethasone enhance the activity of 
ondansetron and are given concurrently. Neurokinin 1 receptor antagonists such as 
aprepitant augment the anti-emetic regimen and primarily treat delayed vomiting.   The 
standard of care for anti-emetics previous to dissemination of the new COG guidelines 
was to prescribe ondansetron for prophylaxis of CINV scheduled every 6 hours during 
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each day of chemotherapy and for 24-48 hours afterward.   Aprepitant, to prevent delayed 
vomiting, was prescribed for patients older than 12 years of age.  For patients that were 
able to receive steroids, dexamethasone was given every 24 hours. Diphenhydramine and 
metoclopramide were used as second line for breakthrough nausea and vomiting, and 
lorazepam was used as third line treatment for breakthrough symptoms.  The timing and 
dosing of this standard anti-emetic regimen was based on adult guidelines; published 
pediatric studies; and institutional provider preference related to adverse events from 
these medications.   
          A multi-disciplinary task force at the pediatric hospital (where the data was 
collected) reviewed the new pediatric anti-emetic guidelines and the associated evidence. 
The team decided to implement the guidelines with a few minor deviations based on the 
level of evidence; clinical contributions from team members; and the potential for 
increased toxicity.   The guidelines endorsed by the Children’s Oncology Group were 
adapted and then disseminated to the hematology/oncology division at Saint Louis 
Children’s Hospital (SLCH) in October of 2017 as a new adapted anti-emetic guideline.  
The differences in the COG guidelines and the new SLCH adapted guideline are outlined 
in Table 1.  In these adapted guidelines the interval of administration of dexamethasone 
for anti-emetic prophylaxis was changed from the recommended every 6 hour to every 12 
hours. The task force intentionally modified this recommendation for dexamethasone as 
the published evidence review was graded, and every 6 hour dosing was a weak 
recommendation with a low quality of evidence (for highly emetic chemotherapy agents).  
Evidence Identification and Synthesis 
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 A review of the literature regarding the previous standard of antiemetic regimens 
to control CINV in pediatric patients was performed. The search terms used were: 
therapeutics, child, nausea, oncology or cancer. The National Center for Biotechnology 
Information (NCBI) database and PubMed were searched using these terms with the 
filters of less than 18 years old and only articles in English. There were 67 results to be 
screened after duplicates were removed. Of these 67 results, 56 record were excluded for 
titles and abstracts not applicable. Eleven full articles were assessed for eligibility. Six 
records were included in the synthesis.  
 In the study published by Cubeddu, Hoffmann, Fuenmayor, & Finn (1990), the 
efficacy of ondansetron to treat CINV in a double blind randomized controlled trial was 
evaluated.  This study demonstrated that ondansetron was superior to a placebo in all 
aspects of antiemetic efficacy. This historical study was included in the synthesis as it set 
the standard for ondansetron as the mainstay of antiemetic therapy for pediatric patients 
receiving chemotherapy.  There were no more recent studies evaluating the efficacy of 
ondansetron in CINV; and 5-HT3 antagonists (like ondansetron) remain the backbone of 
ASCO and POGO recommendations for control of CINV.  
          Anti-emetic agents given in combination with ondansetron have been inconsistent 
in pediatric oncology practice even though there is data to suggest that multi-agent 
treatment for CINV is the most efficacious. The Oncology Nursing Society (ONS) has 
published practice recommendations that are applicable to the pediatric population that 
include 5-HT3 (ondansetron or second generation drug) for prophylaxis of CINV 
(Oncology Nursing Society, 2014). Triple drug therapy with 5-HT3 agonist, 
dexamethasone, and aprepitant is the adult standard of care in ONS guidelines.  A meta-
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analysis of antiemetic medications for the prevention and treatment of CINV concluded 
that 5-HT3 antagonists remain the gold standard and are more effective than older agents, 
and that the addition of dexamethasone to this regimen improves efficacy (Phillips et al., 
2016). Aprepitant is a newer medication that is recommended for adults receiving 
chemotherapy in addition to 5-HT3 antagonists and dexamethasone. There was limited 
data regarding aprepitant in pediatric patients and previous to the new COG guidelines, it 
was not recommended for children under the age of 12 years. A study of aprepitant was 
completed in 2014 to assess the effect and safety of aprepitant in children receiving 
highly emetogenic chemotherapy. The results of this study concluded that much like 
adult data has shown, aprepitant is a safe and effective drug that significantly decreases 
CINV in pediatric patients when used in conjunction with dexamethasone and 
ondansetron (Bakhshi et al., 2015).  
 A second literature review was performed regarding the adoption and use of new 
evidence based guidelines by healthcare providers. The search terms used were: barriers 
or obstacles, provider, guidelines or protocols, implementation. These terms were used to 
search the Medline database. A total of 251 records were identified and screened. Two 
hundred thirty seven records were excluded for title or by abstract. Fourteen full text 
articles were assessed for eligibility. Only records in English were evaluated.  
 According to Okene & Zapka (2000) despite dissemination of clinical practice 
guidelines, adherence to these guidelines for clinical care is often low. Inconsistent use of 
clinical practice guidelines remains a continued challenge to improve public health (Chan 
et al., 2017). There are many barriers to implementation of clinical practice guidelines. 
Some providers do not believe there is a need for a change in clinical standards that are 
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well established.  Although many studies have shown that evidence based guidelines 
and/or clinical practice guidelines can have a positive impact on patient outcomes, many 
clinicians do not readily accept changes to their current practice (Okene & Zapka, 2000). 
Improved dissemination and education could improve provider compliance to evidence 
based practice guidelines (Okene & Zapka, 2000). A study by Zeng et al. (2017) showed 
that even though providers were aware of clinical practice guidelines, only a small 
percentage of them implemented the findings. Of the providers surveyed, the most 
frequently reported barriers to guideline implantation were: lack of training, lack of 
access, and lack of awareness. Although there is scant literature regarding barriers to 
clinical practice guideline implementation, what does exist reflects that a lack of 
knowledge and education on the guidelines remain the primary barriers to changing 
practice.  
Method 
 The overall design of this project was a retrospective chart review to evaluate the 
adherence to implementation of the new pediatric guideline; and to assess outcomes for 
patients who were treated according to the new guideline.  Documentation of 
“breakthrough” medications was used as the key outcome measure to assess if the 
guideline medications worked as intended to control all symptoms of nausea and 
vomiting after chemotherapy. The adapted guidelines were disseminated to the 
hematology/oncology division at SLCH in October of 2017. Charts at this single 
institution were reviewed for patients who received chemotherapy during a planned 
chemotherapy admission between January 2017 and March 2017. Inclusion criteria for 
the chart review included all planned admissions with a patient receiving chemotherapy 
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classified as highly emetogenic per COG anti emetic guidelines. Exclusion criteria for the 
chart review were the following: outpatient chemotherapy treatments; patients that 
received therapy categorized as moderately or mildly emetogenic as delineated in the 
COG antiemetic guidelines; patients that were unable to receive 5-HT3 antagonist for 
comorbid conditions such as prolonged QT; and patients unable to receive steroids. 
Conditions for which steroids are contraindicated as prophylaxis for CINV include but 
are not limited to: patients receiving therapy for leukemia, patients being treated for brain 
tumors, and comorbid conditions such as avascular necrosis. 
The patients who were admitted from January 1, 2017- March 31, 2017 were 
accessed through a list of pre-certifications for insurance approval on a shared drive 
within the division. All patients that were directly admitted to the inpatient oncology 
service, or admitted through the outpatient oncology clinic were on this master list. These 
patients were screened for any exclusion criteria. Patients that had more than one 
admission within this time frame were treated as separate encounters for the chart review.  
The same lists was accessed for January 1, 2018- March 31, 2018. For both chart reviews 
all patients were screened for: administration of chemotherapy categorized as highly 
emetogenic; greater than 6 months of age as this is the youngest patient able to receive 
aprepitant; and no contraindications for use of ondansetron or dexamethasone. These 
contraindications included, but are not limited to: prolonged QTc and allergy to 5-HT3 
agonists.  
 Each patient chart that met criteria for inclusion had the following data extracted 
from the chart: age, gender, number of days patient admitted for treatment, and number 
and type of PRN medications received for breakthrough CINV. In the review of the first 
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quarter of 2018, it was evaluated if the guidelines were followed when prescribing the 
chemotherapy for each admission, and if that provider was an APN or MD. Results were 
tracked using the data collection tool (Appendix A). All patient identifiers were removed. 
Each patient chart was only accessed once. Data was numbered sequentially starting with 
number 1. Data collected from patient charts from January1, 2017- March 31, 2017 will 
be coded with the letter “a” following the number. Data collected from patient charts 
from January 1, 2018-March 31, 2018 will be coded with the letter “b” after the number.  
Results 
 Seventy-six patient’s charts met eligibility criteria and underwent review. Forty-
three of those charts were patient admissions between January 1, 2017 and March 31, 
2017. The remaining thirty-three charts reviewed were patient admissions between 
January 1, 2018 and March 31, 2018. In 2017, the sample included 58%, and 58% of the 
children were less than twelve years old. In 2018, the sample included 64%; and 52% of 
the children were less than twelve years old. The mean age of patients in 2017 was 
9.07±6.19; and in 2018 the mean patient age was 9.47±6.15. 
 A t-test was used to compare the mean number of combined anti-emetic doses for 
all patients in the first quarter of 2017, with the sample from the first quarter of 2018. The 
mean anti-emetic dose for breakthrough CINV in 2017 was 4.837±10.4857, and in 2018 
the mean anti-emetic dose was 3.394±6.432. This was not statistically significant (p 
=0.462) as shown in Table 3. It was then compared by the number of patients in each 
sample. In the first quarter of 2017, 21 patients (49%) received anti-emetics for 
breakthrough CINV as compared to 15 patients (46%) in 2018. A chi square was 
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performed and this was found not to be statistically significant (p =0.77). Both of these 
results are shown in Table 2.  
The patients were then divided into two groups by age for additional analysis. The 
age of 12 years was chosen as the new guideline had the greatest potential impact on 
children less than 12 years of age who were now able to get three agents up front to 
control their nausea and vomiting (ondansetron, dexamethasone and aprepitant).   A t-test 
was performed to compare the mean number of combined anti-emetic doses for patients 
<12 years old in the first quarter of 2017, and in the first quarter of 2018. The mean anti-
emetic dose for 2017 was 5.8±12.5333; and in 2018 the mean was 3.882±8.1. This was 
found to not be statistically significant (p =0.55) as shown in Table 4.  
Conclusion  
          The data from this project did demonstrate that there was excellent adherence with 
use of the new SLCH adapted pediatric anti-emetic guideline in this population of 
patients.   Of the 33 patient charts reviewed, 30 patients (91%) received anti-emetics 
recommended in the adapted guideline.  In reviewing the analysis of the need for anti-
emetic doses to treat breakthrough CINV, it can be concluded that in the population of 
children evaluated in this project, there was not a statistically significant difference in 
control of acute nausea/vomiting after implementation of the new adapted pediatric 
guideline.  This data may suggest that the previous institutional standard regimen at the 
hospital was successful in managing acute nausea and vomiting prior to the 
recommended changes in the new pediatric guideline.  However, in the age group of 
children less than 12 years of age, children did receive 2 fewer prn anti-emetic 
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medications for breakthrough symptoms each admission for chemotherapy treatment 
after guideline implementation. The small sample size in children less than 12 years 
likely impacted the ability to achieve any statistical significance.  Although the data in 
the sample did not achieve statistical significance, this decrease in anti-emetics in 
children less than 12 years of age is clinically significant. Fewer doses of breakthrough 
medications for symptoms of nausea or vomiting would have significantly impacted the 
patient’s overall CINV control; and their quality of life if this would have been an 
outcome measure.  
Discussion  
 One of the biggest changes in the new adapted pediatric guideline was a 
significant increase in the dosing of dexamethasone (twice the dose). These findings 
illustrate similar control of acute CINV with once daily dosing of dexamethasone as 
opposed to the new guideline standard of every 12 hours. The acute side effects of 
dexamethasone used for CINV were studied by Vardy, Chiew, Galica, Pond, & Tannock 
(2006). The four symptoms reported were: insomnia, gastro-esophageal reflux, agitation 
and depression. In fact, 27% of patients reported moderate to severe symptoms in two of 
four categories in the weeks following dexamethasone administration; and 32% reported 
moderate to severe symptoms in at least three of these categories. These severe side 
effects from the anti-emetic itself may negatively impact quality of life. While the use of 
dexamethasone has been well established as an effective agent to prevent both acute and 
delayed nausea and vomiting, the unwanted side effects of increased doses may be 
substantial without increased efficacy.  CINV has negative effects on QoL, however, 
there are many factors that affect QoL. Patients with minimal CINV may have decrease 
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in QoL from the side effects of dexamethasone for CINV prophylaxis (Vardy et al, 2006). 
Providers should take into consideration that a similar dose of dexamethasone once daily 
in this population of patients, was just as effective as an every 12 hour dose for the 
duration of therapy without the risk of increased adverse side effects secondary to high 
dose steroid administration for CINV. 
 The second major change in the new pediatric guideline was the use of aprepitant 
in all children older than 6 months of age.  Aprepitant was designed to control delayed 
vomiting in the time frame from 2-8 days post chemotherapy treatment. Previously, 
patients younger than 12 years old, did not receive aprepitant for CINV. Although 
aprepitant has been shown to be a highly effective ameliorator of delayed CINV, these 
effects may not be seen while the patient is still admitted but would occur after the child 
is discharged from the hospital.  The prevalence of delayed vomiting in children after 
moderately high or highly emetogenic chemotherapy was reported to be as high as 32% 
in a study by Robinson & Carr (2007) specifically addressing the prevalence and pattern 
of these symptoms in children.  The data collected for this project was only during the 
admission for actual treatment and did not include any post treatment follow up. 
Although data collected in the project did not show a statistical difference in acute 
vomiting control; the use of aprepitant in children is still highly recommended as the goal 
is the prevention of delayed vomiting that occurs up to one week after treatment.   
 In terms of adaptation of the new pediatric guideline, the pediatric oncology team 
was very successful with a greater than 90% compliance with the new recommendations. 
Provider compliance with new evidence based guidelines has been well studied. 
However, there is a paucity of literature on effective ways to increase use of guidelines in 
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practice. Studies have shown 30-40% of patients do not receive medical care based on 
scientific evidence, and 25-30% of care is not needed or potentially harmful (Grol & 
Grimshaw, 2003). Barriers to provider use of guidelines at many different points of care. 
These barriers exists at the level of the patient, the provider, the healthcare team, the 
health care organization and the healthcare environment (Grol & Grimshaw, 2003). Lack 
of knowledge by the provider continues to be the most studied barrier to new guideline 
implementation (Maue, Segal, Kimberlan, & Lipowski, 2004).  
 The new adapted guidelines for the prophylaxis of CINV were disseminated via 
division email and discussed at team meetings. There was no formal education on the use 
of the new guidelines prior to or after dissemination. However, there were pre-built anti-
emetic order sets in the provider order entry system that provided clinical guidance on the 
drugs and dosing directly from the new pediatric guidelines. Future interventions to 
improve provider use of institutional guidelines could include focused education with 
providers who are prescribers of chemotherapy. Increased education of bedside nurses 
who are administering highly emetogenic chemotherapies may also be beneficial. The 
bedside nurse could play a crucial role by recognition that a patient receiving highly 
emetogenic chemotherapy was being undertreated for CINV and alert a provider.  
Limitations 
 The findings of this study are limited by the review of patient charts at a single 
institution, and by a small sample size.  In addition, the incidence of nausea and vomiting 
in young children may be effected by the child’s inability to verbalize nausea. Discomfort 
in a child may be perceived by the caregiver as pain or general irritability, and therefore 
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not treated.  There are also limited validated tools in pediatrics to clearly assess and rate 
the distressing symptoms of nausea for children of all ages.  
Conclusions   
 CINV is a distressing symptom of treatment for cancer that negatively impacts the 
patient’s quality of life. This side effect is equally as distressing for children as it is 
adults. While treatment for CINV has been well studied in adults, there is less definitive 
evidence for effective prevention in the pediatric population.  Recent guidelines have 
been published to specifically address prophylaxis of nausea and vomiting in children 
receiving chemotherapy. Providers who prescribe anti-emetics for children receiving 
highly emetic chemotherapy need to carefully review the current data; new published 
guidelines; level of evidence; drug interactions; and side effect profile of available anti-
emetics, and make informed choices in the clinical care of their patients.  As always, 
individual tolerance and patient preference should be a part of clinical care.   Process 
measures and outcome measures after implementation of any new guideline are crucial to 
follow the success of the implementation; and to continually improve the supportive care 
we provide to both adults and children with cancer. 
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Table 1. Changes to Anti-emetic prescribing recommendations. 
Previous Institutional 
Standard of Care 
New Children’s Oncology 
Group Guidelines 
Adapted Guidelines now used 
at St. Louis Children’s 
Hospital 
Ondansetron 
Every 6 hours while receiving 
chemotherapy 
 
 
 
Dexamethasone 
0.2mg/kg every 24 hours if 
unable to receive aprepitant. 
0.1mg/kg every 24 hours if 
concurrently receiving 
aprepitant 
 
Aprepitant 
125mg on day 1 of 
chemotherapy 
80mg on days 2 & 3 of 
chemotherapy only in patients 
greater than 12 years old 
 
 
 
 
 
 
 
Benadryl 
PRN 1mg/kg every 6 hours 
concurrently with 
metoclopramide 
 
Metoclopramide 
PRN 0.3mg/kg every 6 hours 
 
Lorazepam 
PRN 0.02mg/kg every 6 hours 
 
Ondansetron or Granisetron  
Prior to initiation of 
chemotherapy and then q 8 
hours 
 
 
 
Dexamethasone 
6 mg/m2 every 6 hours if 
unable to receive aprepitant 
3 mg/m2 every 6 hours if 
concurrently receiving 
aprepitant 
 
Aprepitant 
125mg on day 1 of 
chemotherapy or 3mg/kg for 
patients old but greater than 6 
months old and less than 12 
years old 
80mg on days 2&3 of 
chemotherapy or 2mg/kg for 
patients greater than 6 months 
old and less than12 years old 
and greater than 6 months old 
 
 
*No recommendations for 
breakthrough nausea and 
vomiting* 
Ondansetron 
Every 6 hours while receiving 
chemotherapy 
 
  
   
Dexamethasone 
6 mg/m2 every 12 hours if 
unable to receive aprepitant 
3 mg/m2 every 12 hours if 
concurrently receiving 
aprepitant 
 
Aprepitant 
125mg on day 1 of 
chemotherapy or 3mg/kg for 
patients old but greater than 6 
months old and less than 12 
years old 
80mg on days 2&3 of 
chemotherapy or 2mg/kg for 
patients greater than 6 months 
old and less than12 years old 
and greater than 6 months old 
 
 
Benadryl 
PRN 1mg/kg every 6 hours 
concurrently with 
metoclopramide 
 
Metoclopramide 
PRN 0.3mg/kg every 6 hours 
 
Lorazepam 
PRN 0.02mg/kg every 6 hours 
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Table 2. T-Test Comparison of Mean Anti-Emetic Doses  Between 2017 & 2018 
 
Year N Mean Std. Deviation Std. Error Mean 
2017 43 4.837 10.4857 1.599 
2018 33 3.394 6.432 1.1197 
Independent Samples Test 
 Levine’s 
Test for 
Equality of 
Variances 
T-Test for Equality of Means 
 F Sig. t df Sig.  Mean 
Difference 
Std Error 
Difference 
95% 
CI 
Lower 
95%CI 
Upper 
Equal 
Variance 
assumed 
1.887 0.174 0.696 74 0.489 1.4433 2.0739 -
2.6888 
5.5753 
Equal 
Variance 
not 
Assumed 
  0.739 0.462 0.462 1.4433 1.9521 -
2.4492 
5.3357 
 
*Pearson Chi Square Test 
Table 4. Comparison of Mean Anti-Emetic Doses Between 2017 & 2018 (<12 years old) 
 
Year N Mean Std. Deviation Std. Error Mean 
2017 25 5.8 12.533 2.5067 
2018 17 3.882 8.1 1.9645 
Independent Samples Test 
 Levine’s Test 
for Equality 
of Variance 
T-Test for Equality of Means 
 F Sig. T Df Sig. Mean 
Difference 
Std. Error 
Difference 
95% 
CI 
lower 
95% 
CI 
upper 
Equal 
Variance 
Assumed 
0.756 0.39 0.556 40 0.581 1.1976 3.4507 -
5.0566 
8.8919 
Equal 
Variance 
Not 
Assumed 
  0.602 0.55 0.55 1.9176 3.1848 -
4.5193 
8.3546 
Table 3. Chi Square Comparison of Anti-Emetic Doses Between 2017 & 2018 
 
Received Anti-
Emetics 
2017 n(%) 2018 n(%) p-value* 
Yes 21 (49%) 15(46%) 0.770 
No 22 (51%) 18(54%)  
    
23 
Implementation of National Pediatric Guidelines 
 
Appendix 
Data Collection Form  
 
Year ________       Chart # _________        Gender___________    Age_________ 
 
Days in hospital __________  
 
Number of doses of: 
Benadryl_________ 
Metoclopramide_____________ 
Lorazepam____________ 
 
 Used anti-emetic prescribing guidelines 
 
 Did not use anti-emetic prescribing guidelines 
o Greater than 6 months and did not receive aprepitant 
o Did not get correct steroid dose/interval 
 
 
